locally-advanced Anal Carcinoma, Anal cancer stage II and III research hub

RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma; A multicenter, randomized, phase II trial of the German Anal Cancer Study Group

This study tests whether adding an immunotherapy medicine called durvalumab to standard chemotherapy and radiotherapy helps treat stage 2 and 3 anal cancer. Doctors want to see if this combination stops the cancer from returning, lowers the need for stoma surgery, and helps people live longer, healthier lives.